NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study with Phase 2 expansion cohort. Phase 1 will assess the safety and
tolerability of autologous expanded NK cells in combination with irinotecan, temozolomide,
and dinituximab. The phase 2 of the study will estimate the response to treatment.